New York, USA – October 23, 2020 – Since the outbreak of the SARS-CoV-2, the entire global health system is threatened and almost every country focuses its energy on developing corresponding therapies, such as the COVID-19 vaccines. By now, there are 41.7M confirmed cases worldwide, yet not a single vaccine candidate has accomplished its phase III clinical trial. Despite the challenging situation, Creative Biolabs is working diligently towards improving new drug development to conquer a wide variety of diseases. Based upon the powerful antibody production platform, high-standard neutralizing antibodies are offered for a wide range of research areas, such as infectious diseases (HCV neutralizing antibodies) detection, cardiovascular disease microscopic research, and cancer microscopic research.
All the offered antibodies are classified into three groups according to their properties, primary antibody, secondary antibody, and isotype controls.
A primary antibody can bind to the designated antigen specifically, which applies to a variety of research assays, such as enzyme-linked immunosorbent assay (ELISA), flow cytometry (FC), western blot (WB), immunofluorescence (IF), immunohistochemistry (IHC) and immunocytochemistry (ICC), and broad research areas, such as cellular marker, signal pathway, stem cell, etc.
Secondary antibodies, usually labeled with fluorescent dyes or enzymes, directly bind to the targeting antigen, providing signal detection and amplification, which are raised against the host species of primary antibodies.
Creative Biolabs provides isotype controls that can be used as negative controls to detect signals caused by off-target binding activities. Three aspects need to be taken into consideration when making selections, which are specificity, host species, and conjugation.
* Human IgG1/IgG2 Isotype Control
* Mouse IgG2a/IgG2b Isotype Control
* Rat IgG2a/IgG2b Isotype Control
* Rabbit IgG Isotype Control
In addition to the above-mentioned antibodies, neutralizing antibodies for the study on the COVID-19 have received popularity among worldwide clients, which are against several essential targets of SARS-CoV-2, including spike S2, spike RBD, matrix protein, and ACE2 receptor, and so on. The products are well in stock and ready for quick delivery to expedite the project progress.
More details can be accessed at https://neutab.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs is a custom service provider in the field of antibody development and engineering, which was established in 2004 in New York. After years of exploration and expansion, the enterprise has grown up into a leading figure in the biopharmaceutical field, which has established long-term cooperation with many pharmaceutical companies, research centers, and universities.